Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where William Glen Harter is active.

Publication


Featured researches published by William Glen Harter.


Journal of Medicinal Chemistry | 2008

Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications.

Jie Jack Li; Donna M. Iula; Maria N. Nguyen; Lain-Yen Hu; Danielle Dettling; Theodore R. Johnson; Daniel Y. Du; Veerabahu Shanmugasundaram; Jennifer A. Van Camp; Zhi Wang; William Glen Harter; Wen-Song Yue; Mark L. Boys; Kimberly Wade; Elena M. Drummond; Brian Samas; Bruce Allen Lefker; Garrett S. Hoge; Mark J. Lovdahl; Jeffrey Asbill; Matthew Carroll; Mary Ann Meade; Susan Ciotti; Theresa Krieger-Burke

4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity.


Bioorganic & Medicinal Chemistry Letters | 2010

Succinic acid amides as P2-P3 replacements for inhibitors of interleukin-1β converting enzyme (ICE or caspase 1)

Paul Galatsis; Bradley William Caprathe; John Gilmore; Anthony Thomas; Kristin Linn; Susan M. Sheehan; William Glen Harter; Catherine Rose Kostlan; Elizabeth A. Lunney; Charles Stankovic; John Rubin; Kenneth Dale Brady; Hamish Allen; Robert V. Talanian

Succinic acid amides have been found to be effective P2-P3 scaffold replacements for peptidic ICE inhibitors. Heteroarylalkyl fragments occupying the P4 position provided access to compounds with nM affinities. Utilization of an acylal prodrug moiety was required to overcome biopharmaceutical issues which led to the identification of 17f, a potential clinical candidate.


Bioorganic & Medicinal Chemistry Letters | 2010

Smoothened antagonists for hair inhibition.

Jie Jack Li; Veerabahu Shanmugasundaram; Satya Reddy; Laura L. Fleischer; Zenquan Wang; Yvonne Smith; William Glen Harter; Wen-Song Yue; Manju Swaroop; Ling Li; Christy Xiaodong Ji; Danielle Dettling; Bella Osak; Laura Fitzgerald; Robert Conradi

A series of aminomethylpyrazoles were prepared and evaluated using cell-based Smoothened beta-lactamase reporter assay and Smoothened binding assay. Potent Smoothened antagonists 10k and 10l were found to inhibit hair growth in vivo in the C3H/HeN mouse hair growth model. The more selective compound 10l was tested negative in the 3T3 NRU assay, indicating a low risk for causing photo-irritation and was efficacious using the C3H/HeN mouse hair growth model although it was slightly less efficacious than that of the reference compound eflornithine (7).


Bioorganic & Medicinal Chemistry Letters | 2010

Inhibition of interleukin-1β converting enzyme (ICE or caspase 1) by aspartyl acyloxyalkyl ketones and aspartyl amidooxyalkyl ketones

Paul Galatsis; Bradley William Caprathe; Dennis M. Downing; John Gilmore; William Glen Harter; Sheryl Hays; Catherine Rose Kostlan; Kristin Linn; Elizabeth A. Lunney; Kim Para; Anthony Thomas; Joseph Scott Warmus; Hamish Allen; Kenneth Dale Brady; Robert V. Talanian; Nigel Walker

A series of acyloxyalkyl and amidooxyalkyl ketones appended to a carbobenzyloxy aspartic acid core have been prepared. The most potent of these new inhibitors was 4i with a K(i) of 0.5 microM. These two series provide an improved understanding of the binding requirements for the hydrophobic prime side of ICE.


Archive | 1997

ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME

Hans-Peter Albrecht; Hamish Allen; Kenneth Dale Brady; Bradley William Caprathe; John L. Gilmore; William Glen Harter; Sheryl J. Hays; Catherine Rose Kostlan; Elizabeth A. Lunney; Kimberly Suzanne Para; Anthony Jerome Thomas; Nigel Walker


Bioorganic & Medicinal Chemistry Letters | 2004

The design and synthesis of sulfonamides as caspase-1 inhibitors.

William Glen Harter; Hans Albrect; Kenneth Dale Brady; Bradley William Caprathe; James B. Dunbar; John Gilmore; Sheryl Hays; Catherine Rose Kostlan; Beth Lunney; Nigel Walker


Archive | 2002

Fused pyrimidinone matrix metalloproteinase inhibitors

William Glen Harter; Jie Jack Li; Daniel F. Ortwine; Kevon Ray Shuler; Wen-Song Yue


Archive | 2002

BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS

Richard D. Dyer; William Glen Harter; James Lester Hicks; Adam R. Johnson; Jie Jack Pfizer Global Res. Dev. Li; William Howard Roark; Kevon Ray Pfizer Global Res. Dev. Shuler


Archive | 2002

Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors

William Glen Harter; Jie Jack Pfizer Global Res. Dev. Li; Daniel Fred Pfizer Global Res. Dev. Ortwine; Kevon Ray Pfizer Global Res. Dev. Shuler; Wen-Song Pfizer Global Res. Dev. Yue


Archive | 1999

SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME

Bradley William Caprathe; John L. Gilmore; William Glen Harter; Sheryl J. Hays; Kristen Michele Knapp; Catherine Rose Kostlan; Elizabeth A. Lunney; Kimberly Suzanne Para; Paul Galatsis; Anthony Jerome Thomas

Collaboration


Dive into the William Glen Harter's collaboration.

Researchain Logo
Decentralizing Knowledge